Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06114940
Other study ID # 2022NZKY-002-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 20, 2022
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Jinling Hospital, China
Contact Le Qu, M.D.
Phone 15720625951
Email septsoul@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this single-center clinical trial was to evaluate the objective response rate and safety of Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib) in neoadjuvant treatment of(T2a-T4NanyM0 or TanyN1M0) clear cell renal cell carcinoma.


Description:

The objective of this single-center clinical trial was to evaluate the objective response rate and safety of Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib) in neoadjuvant treatment of(T2a-T4NanyM0 or TanyN1M0) clear cell renal cell carcinoma.Toripalimab is a new antibody that may help activate the immune system by blocking the function of the inhibitory molecule PD-1. This is a single-institution, single-arm Phase 2 clinical trial. Patients will be treated with Toripalimab in combination with tyrosine kinase inhibitors TKI (Lenvatinib) and patients will undergo partial or radical nephrectomy after neoadjuvant therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Imaging is consistent with(T2a-T4NanyM0 or TanyN1M0) clear cell renal cell carcinoma - Puncture pathological biopsy was consistent with clear cell renal cell carcinoma - Subjects were to undergo radical nephrectomy or partial nephrectomy or enucleation of renal tumor - ECOG 0-1 points -Normal hematopoietic and organ function -- - Understand and plan visits, treatments, laboratory tests, and other research procedures. Exclusion Criteria: - Prior systemic anti-tumor treatment for RCC - Patients who are receiving any other investigational agents. - Clinical status indicating that immediate surgery (within 6 weeks) iswarranted regardless of whether neoadjuvant therapy is to beadministered, as assessed by the treating surgeon. - Inability to undergo baseline tumor biopsy. - Active or prior documented autoimmune or immunocompromisingconditions. - Uncontrolled hypertension - In the investigator's judgment, the subject has a medical history or current evidence of any disease, treatment, or laboratory abnormality that could confuse the results of the trial, interfere with the subject's participation throughout the trial, or is not in the subject's best interest to participate in the trial.

Study Design


Intervention

Drug:
Toripalimab
240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
Lenvatinib
18 mg by mouth once each day for 12 weeks prior to nephrectomy

Locations

Country Name City State
China Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jinling Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate of neoadjuvant treatment of (T2a-T4NanyM0 or TanyN1M0) clear cell renal cell carcinoma with Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib). Tumor response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). week 12 of neoadjuvant treatment
Secondary Safety of neoadjuvant treatment of clear cell renal cell carcinoma with Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib). Safety as assessed by number of participants experiencing adverse events. up to 90 days after end of treatment
Secondary Marginal negative (R0) rate of (T2a-T4NanyM0 or TanyN1M0)clear cell renal cell carcinoma treated with Toripalimab combined with TKI (Lenvatinib). Marginal negative (R0) rate as assessed by number of participants experiencing Marginal negative (R0). Baseline to date of surgery
Secondary Disease-free survival (DFS) in(T2a-T4NanyM0 or TanyN1M0) clear cell renal cell carcinoma treated with Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib) neoadjuvant therapy. DFS was defined as the time from date of surgery to disease recurrence or death whichever occurred first. Up to 5 years after surgery
Secondary Change From Baseline in Myeloid-derived Suppressor Cells (MDSCs) in the Tumor Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean MDSCs using immunohistochemistry. Baseline to date of surgery
Secondary Change From Baseline in Regulatory T-cells (Tregs) in the Tumor Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean Tregs using immunohistochemistry. Baseline to date of surgery
Secondary Change From Baseline in CD4+ T-cells in the Tumor Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean CD4+ T-cells using immunohistochemistry. Baseline to date of surgery
Secondary Change From Baseline in CD8+ T-cells in the Tumor Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean CD8+ T-cells using immunohistochemistry. Baseline to date of surgery
Secondary Change From Baseline in Ratio of Type 1 to Type 2 Tumor Associated Macrophages in the Tumor Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean ratio of Type 1 to Type 2 tumor associated macrophages using immunohistochemistry. Baseline to date of surgery
Secondary Change From Baseline of Selected Cytokines in Peripheral Blood Cytokines measured in peripheral blood were soluble CD27 (sCD27), eotaxin, macrophage inflammatory protein 1b (MIP-1b), and soluble programmed cell death protein 1 (sPD-1). Baseline to Day 43
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab